MT-act

Biotechnology Research • Montpellier, Occitanie, France • 1-10 Employees

Company overview

Headquarters	Montpellier, Occitanie, France
Website	mt-act.com
NAICS	541714
Keywords	Drug Discovery, Drug Development, Drug Screening, Preclinical, Microtubules, Tubulin Code, First-In-Class
Founded	2019
Employees	1-10
Socials

Key Contact at MT-act

Siem Van Der Laan

Ceo / Cso - Management & Technical Enablement

MT-act Email Formats

MT-act uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@mt-act.com), used 80% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@mt-act.com	80%
{first initial}.{last name}	j.doe@mt-act.com	20%

About MT-act

MT-act is a CNRS spin-off. #techtransfer We develop class compounds to treat human pathologies that share a common molecular defect; dysfunction of the skeleton of the cells called microtubules - abbreviated MT. Stiffening of the skeleton of our cells is a central disease driver. That is why we act on them. We developed a technology platform to charter an entirely neglected pharmaceutical space. MT-act prioritizes indications based on scientific evidence, proven unmet medical needs and where the roadmap to patients is feasible and desired.

MT-act revenue & valuation

Annual revenue	$598,885
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$2,000,000
Total funding	No funding